Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

GARY N GROSS

Allopathic & Osteopathic Physicians Allergy & Immunology Allergy

NPI
1285601336
CMS profile
58380
Location
DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$81,721.37

154 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 154 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

GARY N GROSS

NPI 1285601336 · CMS profile ID 58380

Allopathic & Osteopathic Physicians / Allergy & Immunology / Allergy

DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 154 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1285601336?year=2022&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
GARY N GROSS, NPI 1285601336, CMS profile ID 58380. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 154 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1285601336?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). GARY N GROSS, NPI 1285601336, CMS profile ID 58380. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 154 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1285601336?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
GARY N GROSS, NPI 1285601336, CMS profile ID 58380, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 154 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1285601336?year=2022&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

154 matching records · $81,721.37 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 154 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 154.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Regeneron Healthcare Solutions, Inc. $2,802.0004/08/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927186865 CMS
GENZYME CORPORATION $2,569.0004/04/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938740741 CMS
GENZYME CORPORATION $342.2004/04/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938740743 CMS
GENZYME CORPORATION $51.4204/04/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938740745 CMS
GENZYME CORPORATION $51.4004/04/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938740755 CMS
GENZYME CORPORATION $124.7204/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938740757 CMS
GENZYME CORPORATION $2,102.0004/04/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938740759 CMS
GENZYME CORPORATION $342.0904/04/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938740761 CMS
GENZYME CORPORATION $4,203.0004/04/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938740775 CMS
GENZYME CORPORATION $48.5004/04/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938740777 CMS
GENZYME CORPORATION $3.2504/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938740779 CMS
GENZYME CORPORATION $342.0904/04/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938740781 CMS
GENZYME CORPORATION $55.9004/04/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938740783 CMS
GENZYME CORPORATION $10.1804/04/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938740785 CMS
GENZYME CORPORATION $32.5404/04/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938740787 CMS
Regeneron Healthcare Solutions, Inc. $77.9404/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927186859 CMS
GlaxoSmithKline, LLC. $13.7704/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944406545 CMS
AstraZeneca Pharmaceuticals LP $12.8203/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920239605 CMS
AstraZeneca Pharmaceuticals LP $20.0003/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920241433 CMS
Grifols USA, LLC $18.0203/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918674593 CMS
Takeda Pharmaceuticals U.S.A., Inc. $19.4003/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955647121 CMS
LEO Pharma Inc. $30.2003/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 936224551 CMS
Covis Pharma GmBH $17.2203/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 953398879 CMS
ABBVIE INC. $19.2403/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892693521 CMS
OptiNose US, Inc. $2,500.0003/03/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 928121531 CMS
OptiNose US, Inc. $51.8403/03/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 928121535 CMS
OptiNose US, Inc. $35.2503/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 928121543 CMS
OptiNose US, Inc. $55.7503/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 928121547 CMS
OptiNose US, Inc. $24.2803/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 928121551 CMS
OptiNose US, Inc. $270.0703/03/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 928121555 CMS
OptiNose US, Inc. $24.2803/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 928121559 CMS
Regeneron Healthcare Solutions, Inc. $27.0003/03/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927186833 CMS
Regeneron Healthcare Solutions, Inc. $9.6003/03/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927186839 CMS
Regeneron Healthcare Solutions, Inc. $22.8203/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927186843 CMS
Regeneron Healthcare Solutions, Inc. $2.9903/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927186850 CMS
Regeneron Healthcare Solutions, Inc. $28.5503/03/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927186855 CMS
OptiNose US, Inc. $134.3303/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 928121539 CMS
Amgen Inc. $16.4403/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939427493 CMS
Regeneron Healthcare Solutions, Inc. $4,203.0003/01/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927186827 CMS
GlaxoSmithKline, LLC. $15.3002/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944406537 CMS
Merck Sharp & Dohme LLC $41.9902/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944479453 CMS
AstraZeneca Pharmaceuticals LP $18.5402/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920239317 CMS
Regeneron Healthcare Solutions, Inc. $166.7502/21/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927186817 CMS
Regeneron Healthcare Solutions, Inc. $166.7502/21/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927186823 CMS
kaleo, Inc. $21.1102/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941017145 CMS
GENZYME CORPORATION $1,401.0001/31/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938740879 CMS
AstraZeneca Pharmaceuticals LP $19.5901/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920247589 CMS
Octapharma USA, Inc. $26.0901/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937552571 CMS
GlaxoSmithKline, LLC. $13.1101/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944406553 CMS
Regeneron Healthcare Solutions, Inc. $312.2001/22/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927186813 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $73,602.40 168
PY2020 $25,023.61 99
PY2021 $69,757.91 160
PY2022 $81,721.37 154
PY2023 $99,086.59 179
PY2024 $139,366.92 187
PY2025 $113,659.13 215

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $790,709.03 73
PY2024 Principal investigator $694,057.65 62
PY2023 Recipient $2,209.93 5
PY2023 Principal investigator $223,012.98 15
PY2022 Principal investigator $129,662.42 37
PY2021 Recipient $750.00 2
PY2021 Principal investigator $360,964.12 90
PY2020 Recipient $2,046.62 11
PY2020 Principal investigator $315,126.28 75
PY2019 Recipient $530.00 1
PY2019 Principal investigator $601,354.76 68

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

73 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 GlaxoSmithKline, LLC. $72.63 12/23/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192115148
Principal investigator 1 GlaxoSmithKline, LLC. $19,880.05 12/23/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192175583
Principal investigator 1 GlaxoSmithKline, LLC. $2,036.70 12/19/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192115140
Principal investigator 1 SANOFI US SERVICES INC. $12,552.00 12/08/2025 Non-covered Recipient Entity
Pharmaceutical Research Consulting Inc
A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) No dispute reported 06/30/2026 1226087160
Principal investigator 1 SANOFI US SERVICES INC. $40.00 12/08/2025 Non-covered Recipient Entity
Pharmaceutical Research Consulting Inc
A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) No dispute reported 06/30/2026 1226087163
Principal investigator 1 SANOFI US SERVICES INC. $80.00 12/08/2025 Non-covered Recipient Entity
Pharmaceutical Research Consulting Inc
A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) No dispute reported 06/30/2026 1226087167
Principal investigator 1 GlaxoSmithKline, LLC. $24,148.80 11/25/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192115123
Principal investigator 1 GlaxoSmithKline, LLC. $25,237.80 11/25/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192115135
Principal investigator 1 SANOFI US SERVICES INC. $40.00 10/20/2025 Non-covered Recipient Entity
Pharmaceutical Research Consulting Inc
A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) No dispute reported 06/30/2026 1226087152
Principal investigator 1 SANOFI US SERVICES INC. $4,874.00 10/20/2025 Non-covered Recipient Entity
Pharmaceutical Research Consulting Inc
A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) No dispute reported 06/30/2026 1226087155
Principal investigator 1 GlaxoSmithKline, LLC. $4,765.50 10/17/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192173673
Principal investigator 1 GlaxoSmithKline, LLC. $3,041.10 10/17/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192175570
Principal investigator 1 Novartis Pharmaceuticals Corporation $620.78 10/08/2025 Non-covered Recipient Entity
THE PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190313167
Principal investigator 1 SANOFI US SERVICES INC. $40.00 10/06/2025 Non-covered Recipient Entity
Pharmaceutical Research Consulting Inc
A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) No dispute reported 06/30/2026 1226087147
Principal investigator 1 GlaxoSmithKline, LLC. $7,288.20 10/02/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192175587
Principal investigator 1 GlaxoSmithKline, LLC. $7,830.90 10/02/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192175597
Principal investigator 1 SANOFI US SERVICES INC. $7,759.00 09/22/2025 Non-covered Recipient Entity
Pharmaceutical Research Consulting Inc
A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) No dispute reported 06/30/2026 1226087141
Principal investigator 1 Genentech, Inc. $933.70 09/10/2025 Non-covered Recipient Entity
PHARMACEUTICAL RESEARCH AND CONSULTING INC
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211637610
Principal investigator 1 Genentech, Inc. $586.90 09/10/2025 Non-covered Recipient Entity
PHARMACEUTICAL RESEARCH AND CONSULTING INC
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211637618
Principal investigator 1 Genentech, Inc. $29.35 09/10/2025 Non-covered Recipient Entity
PHARMACEUTICAL RESEARCH AND CONSULTING INC
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211637627
Principal investigator 1 Genentech, Inc. $46.69 09/10/2025 Non-covered Recipient Entity
PHARMACEUTICAL RESEARCH AND CONSULTING INC
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211637631
Principal investigator 1 GlaxoSmithKline, LLC. $1,184.00 09/08/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192173662
Principal investigator 1 GlaxoSmithKline, LLC. $8,817.30 09/03/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192173682
Principal investigator 1 GlaxoSmithKline, LLC. $4,833.90 09/03/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192173686
Principal investigator 1 SANOFI US SERVICES INC. $2,400.00 09/03/2025 Non-covered Recipient Entity
Pharmaceutical Research Consulting Inc
A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) No dispute reported 06/30/2026 1226087136
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,409.28 08/28/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK
ALTA - Albuterol budesonide Treatment in Acute airway obstruction his is a multi-center randomized double-blind 2-period cross-over study evaluating efficacy and safety of repeated doses of PT027 albuterol budesonide pressurized metered dose inhaler pMDI compared to PT007 albuterol pMDI in participants with asthma and acute airway obstruction induced by 2 mannitol challenges 7 hours apart No dispute reported 06/30/2026 1185549141
Principal investigator 1 Genentech, Inc. $19,261.00 08/20/2025 Non-covered Recipient Entity
PHARMACEUTICAL RESEARCH AND CONSULTING INC
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211637623
Principal investigator 1 SANOFI US SERVICES INC. $19,869.00 08/18/2025 Non-covered Recipient Entity
Pharmaceutical Research Consulting Inc
A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) No dispute reported 06/30/2026 1226087132
Principal investigator 1 GlaxoSmithKline, LLC. $31,886.10 08/13/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192175592
Principal investigator 1 Genentech, Inc. $1,500.00 08/06/2025 Non-covered Recipient Entity
PHARMACEUTICAL RESEARCH AND CONSULTING INC
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211637605
Principal investigator 1 Genentech, Inc. $1,500.00 08/06/2025 Non-covered Recipient Entity
PHARMACEUTICAL RESEARCH AND CONSULTING INC
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211637614
Principal investigator 1 GlaxoSmithKline, LLC. $2,340.00 08/06/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192175579
Principal investigator 1 GlaxoSmithKline, LLC. $2,369.70 08/04/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192175566
Principal investigator 1 GlaxoSmithKline, LLC. $11,688.60 07/23/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192173670
Principal investigator 1 GlaxoSmithKline, LLC. $12,675.00 07/21/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192173678
Principal investigator 1 SANOFI US SERVICES INC. $2,737.00 07/21/2025 Non-covered Recipient Entity
Pharmaceutical Research Consulting Inc
A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) No dispute reported 06/30/2026 1226087129
Principal investigator 1 SANOFI US SERVICES INC. $20,469.00 07/02/2025 Non-covered Recipient Entity
Pharmaceutical Research Consulting Inc
A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) No dispute reported 06/30/2026 1226087121
Principal investigator 1 SANOFI US SERVICES INC. $2,400.00 07/02/2025 Non-covered Recipient Entity
Pharmaceutical Research Consulting Inc
A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) No dispute reported 06/30/2026 1226087125
Principal investigator 1 GlaxoSmithKline, LLC. $6,721.20 06/20/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192115115
Principal investigator 1 GlaxoSmithKline, LLC. $111.10 06/02/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192115155
Principal investigator 1 GlaxoSmithKline, LLC. $5,205.60 05/21/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192173690
Principal investigator 1 SANOFI US SERVICES INC. $11,200.00 05/12/2025 Non-covered Recipient Entity
Pharmaceutical Research Consulting Inc
A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) No dispute reported 06/30/2026 1226087117
Principal investigator 1 AstraZeneca Pharmaceuticals LP $98,710.91 05/08/2025 Non-covered Recipient Entity
PHARMACEUTICALS RESEARCH CONSULTING INC.
A Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared with BDA Delivered by MDI HFA in Participants with Asthma No dispute reported 06/30/2026 1185549147
Principal investigator 1 Genentech, Inc. $518.00 05/07/2025 Non-covered Recipient Entity
PHARMACEUTICAL RESEARCH AND CONSULTING INC
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211637597
Principal investigator 1 AstraZeneca Pharmaceuticals LP $19,376.71 05/01/2025 Non-covered Recipient Entity
PHARMACEUTICALS RESEARCH CONSULTING INC.
A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma No dispute reported 06/30/2026 1185549145
Principal investigator 1 Genentech, Inc. $752.00 04/25/2025 Non-covered Recipient Entity
PHARMACEUTICAL RESEARCH AND CONSULTING INC
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211637568
Principal investigator 1 Genentech, Inc. $530.00 04/25/2025 Non-covered Recipient Entity
PHARMACEUTICAL RESEARCH AND CONSULTING INC
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211637572
Principal investigator 1 Genentech, Inc. $1,128.00 04/25/2025 Non-covered Recipient Entity
PHARMACEUTICAL RESEARCH AND CONSULTING INC
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211637577
Principal investigator 1 Genentech, Inc. $51.00 04/25/2025 Non-covered Recipient Entity
PHARMACEUTICAL RESEARCH AND CONSULTING INC
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211637584
Principal investigator 1 Genentech, Inc. $180.00 04/25/2025 Non-covered Recipient Entity
PHARMACEUTICAL RESEARCH AND CONSULTING INC
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211637589
Principal investigator 1 Genentech, Inc. $39.00 04/25/2025 Non-covered Recipient Entity
PHARMACEUTICAL RESEARCH AND CONSULTING INC
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211637593
Principal investigator 1 Genentech, Inc. $89.70 04/25/2025 Non-covered Recipient Entity
PHARMACEUTICAL RESEARCH AND CONSULTING INC
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211637601
Principal investigator 1 GlaxoSmithKline, LLC. $6,147.00 04/23/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192175561
Principal investigator 1 AstraZeneca Pharmaceuticals LP $39,359.81 04/15/2025 Non-covered Recipient Entity
PHARMACEUTICALS RESEARCH CONSULTING INC.
a randomized,double blind,multicenter,parallel group,phase IIIb 52 week study evaluating the efficacy and safety of PT027 compared with PT007 administered as needed in participants 12 to under 18 years of age with asthma ACADIA No dispute reported 06/30/2026 1185549151
Principal investigator 1 GlaxoSmithKline, LLC. $8,013.60 02/25/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192175575
Principal investigator 1 AstraZeneca Pharmaceuticals LP $12,312.28 02/20/2025 Non-covered Recipient Entity
PHARMACEUTICALS RESEARCH CONSULTING INC.
a randomized,double blind,multicenter,parallel group,phase IIIb 52 week study evaluating the efficacy and safety of PT027 compared with PT007 administered as needed in participants 12 to under 18 years of age with asthma ACADIA No dispute reported 06/30/2026 1185549153
Principal investigator 1 Genentech, Inc. $3,000.00 02/14/2025 Non-covered Recipient Entity
PHARMACEUTICAL RESEARCH AND CONSULTING INC
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211637545
Principal investigator 1 Genentech, Inc. $3,259.00 02/14/2025 Non-covered Recipient Entity
PHARMACEUTICAL RESEARCH AND CONSULTING INC
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211637550
Principal investigator 1 AstraZeneca UK Limited $57,190.45 02/13/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK
a randomized,double blind,multicenter,parallel group,phase IIIb 52 week study evaluating the efficacy and safety of PT027 compared with PT007 administered as needed in participants 12 to under 18 years of age with asthma ACADIA No dispute reported 06/30/2026 1185549135
Principal investigator 1 Genentech, Inc. $371.00 02/05/2025 Non-covered Recipient Entity
PHARMACEUTICAL RESEARCH AND CONSULTING INC
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211637538
Principal investigator 1 Genentech, Inc. $165.00 02/05/2025 Non-covered Recipient Entity
PHARMACEUTICAL RESEARCH AND CONSULTING INC
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211637564
Principal investigator 1 AstraZeneca Pharmaceuticals LP $25,712.01 01/31/2025 Non-covered Recipient Entity
PHARMACEUTICALS RESEARCH CONSULTING INC.
A Multicenter Randomized Double Blind Parallel Group Placebo Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Patients with Severe Chronic Rhinosinusitis with Nasal Polyposis WAYPOINT No dispute reported 06/30/2026 1185549137
Principal investigator 1 GlaxoSmithKline, LLC. $12,865.50 01/24/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192173666
Principal investigator 1 AstraZeneca Pharmaceuticals LP $35,266.62 01/23/2025 Non-covered Recipient Entity
PHARMACEUTICALS RESEARCH CONSULTING INC.
A Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared with BDA Delivered by MDI HFA in Participants with Asthma No dispute reported 06/30/2026 1185549133
Principal investigator 1 AstraZeneca Pharmaceuticals LP $546.55 01/23/2025 Non-covered Recipient Entity
PHARMACEUTICALS RESEARCH CONSULTING INC.
A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma No dispute reported 06/30/2026 1185549143
Principal investigator 1 AstraZeneca Pharmaceuticals LP $21,427.34 01/22/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK
A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma No dispute reported 06/30/2026 1185549149
Principal investigator 1 AstraZeneca Pharmaceuticals LP $148,789.91 01/10/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK
A Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared with BDA Delivered by MDI HFA in Participants with Asthma No dispute reported 06/30/2026 1185549139
Principal investigator 1 GlaxoSmithKline, LLC. $215.91 01/08/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192115129
Principal investigator 1 Genentech, Inc. $135.85 01/03/2025 Non-covered Recipient Entity
PHARMACEUTICAL RESEARCH AND CONSULTING INC
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211637535
Principal investigator 1 Genentech, Inc. $950.00 01/03/2025 Non-covered Recipient Entity
PHARMACEUTICAL RESEARCH AND CONSULTING INC
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211637542
Principal investigator 1 Genentech, Inc. $452.00 01/03/2025 Non-covered Recipient Entity
PHARMACEUTICAL RESEARCH AND CONSULTING INC
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211637555
Principal investigator 1 Genentech, Inc. $560.00 01/03/2025 Non-covered Recipient Entity
PHARMACEUTICAL RESEARCH AND CONSULTING INC
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211637560
Principal investigator 1 Novartis Pharmaceuticals Corporation $112.00 01/01/2025 Non-covered Recipient Entity
PHARMACEUTICAL RESEARCH & CONSULTING INCORPORATION
A 12-week, Multicenter, Randomized, Double-blind, Parallel-arm, Placebo-controlled Study to Assess the Efficacy and Safety of CSJ117, When Added to Existing Asthma Therapy in Patients ? 18 Years of Age With Severe Uncontrolled Asthma. No dispute reported 06/30/2026 1190303491